연구용
Daunorubicin Hydrochloride (Daunomycin) Topoisomerase II 억제제
제품 번호S3035
화학 구조
분자량: 563.98
바로가기
품질 관리
배치:
순도:
99.98%
99.98
세포 배양, 처리 및 작업 농도
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| MDA MB 361(mammary carcinoma cell line) | Cytotoxic assay | The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase), IC50=17 nM | 10395490 | |||
| P388 leukemia cell line | Cytotoxic assay | Compound was evaluated for cytotoxicity against P388 leukemia cell line, IC50=3 nM | 10479297 | |||
| Dx5 w/PSC cell lines | Growth inhibition assay | The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay, IC50=14 nM | 10698449 | |||
| MES-SA uterine tumor cell lines | Growth inhibition assay | The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay, IC50=0.021 μM | 10698449 | |||
| Dx5 cell lines | Growth inhibition assay | The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay, ic50=2 μM | 10698449 | |||
| human epidermoid carcinoma cell line KB-3-1 | Cytotoxic assay | In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1, IC50=7 nM | 12443763 | |||
| human uterine sarcoma cell line MES-SA | Cytotoxic assay | In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA, IC50=0.07 μM | 12443763 | |||
| Jurkat T lymphocytes | Cytotoxic assay | Cytotoxicity against Jurkat T lymphocytes by MTT assay, IC50=0.0826 μM | 16366602 | |||
| human HeLa3 cell line | Cytotoxic assay | Cytotoxicity against human HeLa3 cell line by MTT assay, IC50=2.96 μM | 16942037 | |||
| NCI-H69 cell line | Proliferation assay | Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay, IC50=0.1 μM | 17286393 | |||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.3 μM. | 423181 | |||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 1 μM. | 423181 | |||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation, ED50 = 0.3 μM. | 490537 | |||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation, ED50 = 0.4 μM. | 490537 | |||
| L1210 | Function assay | Inhibition of [3H]uridine incorporation into proliferating L1210 cells, ED50 = 0.33 μM. | 6716401 | |||
| L1210 | Function assay | Inhibition of [3H]thymidine incorporation into proliferating L1210 cells, ED50 = 0.66 μM. | 6716401 | |||
| L1210 | Function assay | Dose required to inhibit the RNA synthesis in leukemia L1210 cells, ED50 = 0.3 μM. | 7252976 | |||
| L1210 | Function assay | Dose required to inhibit the DNA synthesis in leukemia L1210 cells, ED50 = 1 μM. | 7252976 | |||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 0.22 μM. | 17190447 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.25 μM. | 17190447 | ||
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.32 μM. | 17190447 | ||
| PC-3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC-3 cells after 48 hrs by MTT assay, IC50 = 0.44 μM. | 17190447 | ||
| Yoshida sarcoma tumor cells | Function assay | Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats, IC50 = 0.02 μM. | 1322986 | |||
| HL60 | Apoptosis assay | In vitro concentration required to induce apoptosis in HL60 cells, AC50 = 0.04 μM. | 12877593 | |||
| HL60R | Apoptosis assay | In vitro concentration required to induce apoptosis in HL60R cells, AC50 = 10 μM. | 12877593 | |||
| HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method, AC50 = 0.1 μM. | 18339455 | |||
| HL60 | Apoptosis assay | Induction of apoptosis in multidrug resistant human HL60 cells after 48 hrs, AC50 = 38 μM. | 18339455 | |||
| HTB-81 | Cytotoxicity assay | Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in human prostate cancer HTB-81 cells using MTS assay, EC50 = 0.058 μM. | 11020285 | |||
| B16 | Cytotoxicity assay | Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay, EC50 = 0.16 μM. | 11020285 | |||
| fibroblast (NHF) cells | Cytotoxicity assay | Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in normal human fibroblast (NHF) cells using MTS assay, EC50 = 0.22 μM. | 11020285 | |||
| L1210 | Function assay | 3 hrs | Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.3 μM. | 176359 | ||
| L1210 | Function assay | 3 hrs | Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.3 μM. | 176359 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.33 μM. | 423182 | |||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.66 μM. | 423182 | |||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.33 μM. | 490536 | |||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.66 μM. | 490536 | |||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells, ED50 = 0.23 μM. | 690999 | |||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells, ED50 = 0.48 μM. | 690999 | |||
| L1210 | Function assay | Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells), ED50 = 0.33 μM. | 3761325 | |||
| L1210 | Function assay | Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells), ED50 = 0.66 μM. | 3761325 | |||
| L1210 | Function assay | Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells, ED50 = 0.33 μM. | 7086816 | |||
| L1210 | Function assay | Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells, ED50 = 0.66 μM. | 7086816 | |||
| NCI60 | Growth inhibition assay | Growth inhibition of human NCI60 cells, GI50 = 0.044 μM. | 19944612 | |||
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.02 μM. | 19968258 | ||
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.07 μM. | 19968258 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, GI50 = 0.08 μM. | 19968258 | ||
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human K562 cells after 72 hrs by XTT assay, GI50 = 0.0074 μM. | 20591678 | ||
| NCI-H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay, GI50 = 0.38 μM. | 20591678 | ||
| SF268 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SF268 cells after 72 hrs by XTT assay, GI50 = 0.6 μM. | 20591678 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay, GI50 = 0.86 μM. | 20591678 | ||
| Detroit 551 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay, GI50 = 1.77 μM. | 20591678 | ||
| HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis, GI50 = 0.1 μM. | 25874335 | ||
| HL60R | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60R cells expressing p-glycoprotein assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis, GI50 = 38 μM. | 25874335 | ||
| P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 0.028 μM. | 2778449 | ||
| HT-29 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.133 μM. | 2778449 | ||
| HeLa | Function assay | TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells, IC50 = 8 μM. | 8621644 | |||
| breast carcinoma line cells | Function assay | compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells, IC50 = 0.06 μM. | 9258351 | |||
| breast carcinoma line cells | Function assay | compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells, IC50 = 2 μM. | 9258351 | |||
| MCF-7 | Function assay | Compound was tested for its toxicity against human breast cancer cells(MCF-7), IC50 = 0.06 μM. | 9548820 | |||
| MCF-7/ADR | Function assay | Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR), IC50 = 2 μM. | 9548820 | |||
| L1210 | Function assay | Inhibitory activity was measured against murine L1210 leukemia cells, IC50 = 0.03 μM. | 9733483 | |||
| HL60 | Function assay | In vitro inhibitory concentration against proliferation of HL60 cells, IC50 = 0.005 μM. | 12877593 | |||
| HL60R | Function assay | In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil, IC50 = 0.04 μM. | 12877593 | |||
| HL60R | Function assay | In vitro inhibitory concentration against proliferation of HL60R cells, IC50 = 1.5 μM. | 12877593 | |||
| K562 | Cytotoxicity assay | Cytotoxicity against K562 cells by MTS, IC50 = 0.015 μM. | 16451059 | |||
| P388 | Antiproliferative assay | Antiproliferative activity against P388 cells by ELISA, IC50 = 0.025 μM. | 17154505 | |||
| P388 | Antiproliferative assay | Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA, IC50 = 0.04 μM. | 17154505 | |||
| MDA435/LCC6 | Antiproliferative assay | Antiproliferative activity against MDA435/LCC6 cells by ELISA, IC50 = 0.079 μM. | 17154505 | |||
| P388 | Antiproliferative assay | Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA, IC50 = 0.106 μM. | 17154505 | |||
| MDA435/LCC6 | Antiproliferative assay | Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA, IC50 = 0.129 μM. | 17154505 | |||
| MDA435/LCC6 | Antiproliferative assay | Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA, IC50 = 0.977 μM. | 17154505 | |||
| P388 | Antiproliferative assay | Antiproliferative activity against adriamycin resistant P388 cells by ELISA, IC50 = 2.111 μM. | 17154505 | |||
| A2780 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A2780 cells after 72 hrs by MTT assay, IC50 = 0.11749 μM. | 17890094 | ||
| A2780/ADR | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay, IC50 = 18.6209 μM. | 17890094 | ||
| NIH/3T3 | Cytotoxicity assay | 72 hrs | Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay, IC50 = 0.044 μM. | 18954040 | ||
| NIH/3T3 | Cytotoxicity assay | 72 hrs | Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay, IC50 = 1.01 μM. | 18954040 | ||
| KB | Cytotoxicity assay | 48 hrs | Cytotoxicity against human KB cells after 48 hrs by MTT assay, IC50 = 0.64 μM. | 20363142 | ||
| KB-C2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human multidrug-resistant KB-C2 cells after 48 hrs by MTT assay, IC50 = 16.2 μM. | 20363142 | ||
| HT-29 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay, IC50 = 0.4 μM. | 21094049 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay, IC50 = 0.7 μM. | 21094049 | ||
| NIH/3T3 | Cytotoxicity assay | 3 days | Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay, IC50 = 1.8 μM. | 21094049 | ||
| Vero | Cytotoxicity assay | 3 days | Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay, IC50 = 2.5 μM. | 21094049 | ||
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay, IC50 = 5.5 μM. | 21094049 | ||
| CRL7761 | Cytotoxicity assay | 3 days | Cytotoxicity against human CRL7761 cells after 3 days by MTS assay, IC50 = 10.5 μM. | 21094049 | ||
| NCI-H460 | Anticancer assay | Anticancer activity against human NCI-H460 cells, IC50 = 0.38 μM. | 21599000 | |||
| SF268 | Anticancer assay | Anticancer activity against human SF268 cells, IC50 = 0.6 μM. | 21599000 | |||
| MRC5 | Antiproliferative assay | Antiproliferative activity against human MRC5 cells, IC50 = 0.88 μM. | 21599000 | |||
| MCF7 | Anticancer assay | Anticancer activity against human MCF7 cells, IC50 = 5.03 μM. | 21599000 | |||
| DU145 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay, IC50 = 0.09 μM. | 22260166 | ||
| SKMES1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay, IC50 = 0.17 μM. | 22260166 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay, IC50 = 0.95 μM. | 22260166 | ||
| LNCAP | Cytostatic assay | 4 days | Cytostatic activity against human LNCAP cells after 4 days by MTT assay, IC50 = 0.1 μM. | 22480495 | ||
| HT-29 | Cytostatic assay | 4 days | Cytostatic activity against human HT-29 cells after 4 days by MTT assay, IC50 = 0.2 μM. | 22480495 | ||
| MCF7 | Cytostatic assay | 4 days | Cytostatic activity against human MCF7 cells after 4 days by MTT assay, IC50 = 0.4 μM. | 22480495 | ||
| HepG2 | Function assay | HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 2.99 μM. | 22586124 | |||
| THP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay, IC50 = 26.9 μM. | 22939695 | ||
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay, IC50 = 0.3 μM. | 23199479 | ||
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay, IC50 = 0.73 μM. | 23199479 | ||
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay, IC50 = 2.32 μM. | 23199479 | ||
| L5178Y | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay, IC50 = 7.73 μM. | 23199479 | ||
| DA-3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay, IC50 = 1.9 μM. | 24900668 | ||
| SKOV3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay, IC50 = 20.6 μM. | 24900668 | ||
| ES2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human ES2 cells after 24 hrs by XTT assay, IC50 = 25.5 μM. | 24900668 | ||
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay, IC50 = 33.9 μM. | 24900668 | ||
| MRC5 | Antiproliferative assay | Antiproliferative activity against human MRC5 cells by XTT assay, IC50 = 0.078 μM. | 25467291 | |||
| A549 | Antiproliferative assay | Antiproliferative activity against human A549 cells by XTT assay, IC50 = 0.08 μM. | 25467291 | |||
| MDA-MB-231 | Antiproliferative assay | Antiproliferative activity against human MDA-MB-231 cells by XTT assay, IC50 = 0.091 μM. | 25467291 | |||
| H1299 | Antiproliferative assay | Antiproliferative activity against human H1299 cells by XTT assay, IC50 = 0.096 μM. | 25467291 | |||
| MCF7 | Antiproliferative assay | Antiproliferative activity against human MCF7 cells by XTT assay, IC50 = 0.65 μM. | 25467291 | |||
| HEK293 | Cytotoxicity assay | 24 hrs | Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay, IC50 = 12.55 μM. | 26937828 | ||
| MCF7/ADR | Growth inhibition assay | 48 hrs | Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay, IC50 = 7.12 μM. | 28246041 | ||
| HCT16 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human HCT16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 0.21 μM. | 28923382 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 0.51 μM. | 28923382 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 1.44 μM. | 28923382 | ||
| RD | Cytotoxicity assay | 72 hrs | Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 2.45 μM. | 28923382 | ||
| HEK293 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay, IC50 = 11.17 μM. | 28923382 | ||
| CCRF-CEM | Growth inhibition assay | In vitro growth inhibitory activity against CCRF-CEM (human lymphoblastic leukemic) cells, ID50 = 0.04 μM. | 6951049 | |||
| CCRF-CEM | Function assay | Inhibitory activity against CCRF-CEM(human leukemic lymphoblastic) cells in culture, ID50 = 0.04 μM. | 7057426 | |||
| Sf9 | Function assay | TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells, Kact = 2.5 μM. | 11437380 | |||
| GLC4/ADR | Function assay | TP_TRANSPORTER: inhibition of DNP-SG uptake in membrane vesicles from GLC4/ADR cells, Ki = 0.95 μM. | 9188796 | |||
| SR3A | Function assay | TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from SR3A cells, Ki = 0.07 μM. | 9647783 | |||
| Caco-2 | Function assay | TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells, Ki = 2.5 μM. | 11405287 | |||
| MDCK | Function assay | TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells, Ki = 49.4 μM. | 12134946 | |||
| GLC4/ADR | Function assay | TP_TRANSPORTER: efflux in GLC4/ADR cells, Km = 1.4 μM. | 7945406 | |||
| BTI-TN5B1-4 | Function assay | TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells, Km = 1.74 μM. | 11785684 | |||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, LC50 = 0.35 μM. | 19968258 | ||
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, LC50 = 0.86 μM. | 19968258 | ||
| CEM | Cytotoxicity assay | 72 hrs | Cytotoxicity against CEM cells after 72 hrs, TCS50 = 0.062 μM. | 17608396 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against MCF7 cells after 72 hrs, TCS50 = 0.14 μM. | 17608396 | ||
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against K562 cells after 72 hrs, TCS50 = 0.23 μM. | 17608396 | ||
| HOS | Cytotoxicity assay | 72 hrs | Cytotoxicity against HOS cells after 72 hrs, TCS50 = 0.33 μM. | 17608396 | ||
| G361 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human G361 cells after 72 hrs, TCS50 = 0.67 μM. | 17608396 | ||
| HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against HeLa cells after 72 hrs, TCS50 = 0.67 μM. | 17608396 | ||
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, TGI = 0.12 μM. | 19968258 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, TGI = 0.17 μM. | 19968258 | ||
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay, TGI = 0.33 μM. | 19968258 | ||
| K562 | Function assay | Increase in the level of drug uptake in Dox-resistant K562 cells in presence of cyclosporine over its absence | 16451059 | |||
| K562 | Function assay | Increase in the level of drug efflux in Dox-resistant K562 cells in presence of cyclosporine over its absence | 16451059 | |||
| KB | Apoptosis assay | 1 uM | 24 hrs | Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs | 18680275 | |
| DU145 | Function assay | 90 nM | 72 hrs | Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 72 hrs by immunoblot analysis | 22260166 | |
| DU145 | Function assay | 90 nM | 30 mins | Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 30 mins by immunoblot analysis | 22260166 | |
| DU145 | Function assay | 500 nM | 4 hrs | Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 500 nM after 4 hrs by Western blot analysis | 22260166 | |
| DU145 | Function assay | 0.1 to 0.5 uM | 24 hrs | Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis | 22260166 | |
| DA-3 | Cytotoxicity assay | 20 uM | 60 mins | Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 60 mins by XTT assay | 24900668 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| P388 | Antitumor assay | 0.25 to 10 mg/kg | Antitumor activity against mouse P388 cells allografted in mouse assessed as tumor growth inhibition at 0.25 to 10 mg/kg | 1255661 | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
화학 정보, 보관 및 안정성
| 분자량 | 563.98 | 화학식 | C27H29NO10 . HCl |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 23541-50-6 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | Rubidomycin HCl, RP 13057 HCl | Smiles | CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl | ||
용해도
|
In vitro |
DMSO
: 100 mg/mL
(177.31 mM)
Water : 100 mg/mL Ethanol : Insoluble |
몰농도 계산기
희석 계산기
분자량 계산기
|
In vivo |
|||||
생체 내 제형 계산기 (투명한 용액)
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
mg/kg
g
μL
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
작용 메커니즘
| Targets/IC50/Ki |
DNA synthesis
(Cell-free assay) 20 nM(Ki)
|
|---|---|
| 시험관 내(In vitro) |
Daunorubicin 투여 후 최대 혈장 농도를 반영하는 약물 농도에서, 주요 메커니즘은 Topoisomerase II와의 상호작용을 통해 이루어질 가능성이 높으며, 이는 적어도 백혈병 세포 및 흉선세포에서 apoptosis로 이어지는 신호 전달 경로를 통해 성장 정지 및/또는 세포 사멸을 유도하는 주요 촉발 사건이 될 수 있습니다. 퀴논 구조는 Daunorubicin이 사이토크롬 P450 환원효소, NADH 탈수소효소 및 잔틴 산화효소를 포함한 산화환원 효소에 의해 매개되는 반응에서 전자 수용체 역할을 할 수 있게 합니다. 약 2-4 µM을 초과하는 Daunorubicin 농도에서는 자유 라디칼 매개 독성 및 DNA 교차결합이 나타날 수 있습니다. Daunorubicin은 HeLa 세포에서 0.2에서 2 µM 농도 범위에 걸쳐 DNA 및 RNA 합성을 모두 억제합니다. Daunorubicin은 Ehrlich 복수 종양 세포에서 4 µM 농도 범위에 걸쳐 DNA 합성을 억제합니다. Daunorubicin은 HL-60 또는 U-937 인간 백혈병 세포에서 0.5 및 1 µM 농도에서 apoptosis를 유발합니다. Daunorubicin은 세라마이드 합성 효소의 활성화를 통한 신생 합성을 통해 P388 및 U937 세포에서 세라마이드 증가 및 apoptosis를 자극합니다. Daunorubicin은 사람 제대 정맥 내피 세포의 포스파티딜세린 노출 및 결과적인 응고 촉진 활성을 용량 의존적으로 증가시킵니다. Daunorubicin (0.2 mM)은 사람 제대 정맥 내피 세포에서 매우 응고 촉진적인 내피 미세 입자의 방출을 유의하게 증가시킵니다. |
참조 |
|
적용 분야
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | p-Chk1 / Chk1 / p-ATR / ATR |
|
26727128 |
| Immunofluorescence | p-Chk1 |
|
26727128 |
| Growth inhibition assay | Cell viability |
|
30745844 |
임상시험 정보
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT04562792 | Completed | Relapsed Pediatric ALL|Relapsed Pediatric AML|Refractory Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia |
Children''s Mercy Hospital Kansas City |
May 8 2020 | Phase 2 |
| NCT03878927 | Terminated | Acute Myeloid Leukemia |
Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer |
August 23 2019 | Phase 1 |
| NCT03896269 | Recruiting | Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome |
M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
May 14 2019 | Phase 1 |
기술 지원
제품은 연구용으로만 사용됩니다. 인체에는 사용하지 마십시오. 환자에게 판매하지 않습니다.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.